BioPharma Dive January 21, 2025
Sponsored content By Evaluate
Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – inevitably – obesity.Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound are on track to generate over $70bn in combined sales – and they top the charts of the fastest-growing drugs for the year.
The challenge for Novo Nordisk and Lilly, the drugs’ owners, will be staying ahead in a game that is going to become incredibly competitive in the coming years. In the short...
Today's Sponsors
Today's Sponsor